A novel C19ORF12 mutation in two MPAN sisters treated with deferiprone
Abstract Background Mitochondrial membrane protein-associated neurodegeneration (MPAN) is a rare and devastating disease caused by pathogenic mutations in C19orf12 gene. MPAN is characterized by pathological iron accumulation in the brain and fewer than 100 cases of MPAN have been described. Althoug...
Main Authors: | Sihui Chen, Xiaohui Lai, Jiajia Fu, Jing Yang, Bi Zhao, Huifang Shang, Rui Huang, Xueping Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-03-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12883-023-03172-z |
Similar Items
-
Identification of Autophagy as a Functional Target Suitable for the Pharmacological Treatment of Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) In Vitro
by: Enrica Zanuttigh, et al.
Published: (2023-01-01) -
Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy
by: Nicola Romano, et al.
Published: (2022-08-01) -
A Novel Deletion Mutation of Exon 2 of the C19orf12 Gene in an Omani Family with Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN)
by: Nabil Al Macki, et al.
Published: (2017-01-01) -
A pilot trial of deferiprone in pantothenate kinase-associated neurodegeneration patients
by: Mohammad Rohani, et al.
Published: (2018-02-01) -
The Best Iron Chelation Therapy in Major Thalassemia Patients is Combination of Desferrioxamine and Deferiprone
by: Ebrahim miri moghaddam, et al.
Published: (2011-04-01)